Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Chirurgia (Bucharest, Romania : 1990)|July 9, 2018
Managing Infected Pancreatic NecrosisJohn-Edwin Thomson, Sven M Van Dijk, Martin Brand, et al.
Frontiers in Cardiovascular Medicine|November 29, 2023
Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry diseaseChristian Pogoda, Stefan-Martin Brand, Thomas Duning, et al.
Plos One|February 9, 2013
Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A geneMalte Lenders, Thomas Duning, Michael Schelleckes, et al.
Journal of Inherited Metabolic Disease|October 7, 2019
Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activityFranciska Stappers, David Scharnetzki, Boris Schmitz, et al.
Frontiers in Physiology|May 3, 2018
Longer Work/Rest Intervals During High-Intensity Interval Training (HIIT) Lead to Elevated Levels of miR-222 and miR-29cBoris Schmitz, Florian Rolfes, Katrin Schelleckes, et al.
American Journal of Physiology. Heart and Circulatory Physiology|April 13, 2019
Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAsBoris Schmitz, Hannah Niehues, Malte Lenders, et al.
Journal of Molecular and Cellular Cardiology|May 4, 2019
Rare non-coding Desmoglein-2 variant contributes to Arrhythmogenic right ventricular cardiomyopathyAlex Hørby Christensen, Claus B Andersen, Katharina Wassilew, et al.
Clinical Epigenetics|October 20, 2017
Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinomaKatrin Schelleckes, Boris Schmitz, Giuliano Ciarimboli, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 28, 2013
Tissue-specific differences in the regulation of KIBRA gene expression involve transcription factor TCF7L2 and a complex alternative promoter systemKatrin Guske, Boris Schmitz, Michael Schelleckes, et al.
Pageof 13